Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDAAA and labeling

Executive Summary

Former FDAer Greg Burkhart, Burkhart & Freiman, proposes that one aspect of newfound authority that FDA will embrace is the ability to mandate product labeling changes. "You're going to see something a little bit different regarding how safety information may get into the label. There is going to a much bigger push I think coming from certain parts of the agency. It's going to be very difficult for the divisions ... to resist such changes," he said at the DIA session. Disagreements within FDA over the appropriate treatment of safety information have recently been exposed to the public (1"The Pink Sheet" Aug. 6, 2007, p. 6). "It will change the way that the sponsors are notified when FDA thinks something is going on. Before it had to have a high threshold before FDA would even bother because a lot of times there would be a fight. I don't think that is going to be the case anymore. I think things are going to get into the label now from the FDA viewpoint that may have a lower threshold"...

Latest Headlines
See All
UsernamePublicRestriction

Register

PS049205

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel